Search

A 47-year-old woman developed microscopic colitis while being treated with escitalopram for anxiety. She also experienced lack of efficacy with ciprofloxacin and metronidazole for pancolitis. Despite previous medical history including cholecystectomy and treatment with amoxicillin/clavulanic-acid for sinusitis, her symptoms worsened, leading to a diagnosis of lymphocytic colitis associated with escitalopram. Escitalopram was discontinued, and she was subsequently treated with budesonide. [Extracted from the article]

A woman in her 70s experienced drug intolerance and lack of efficacy with various antidepressants for depression, including paroxetine, fluoxetine, sertraline, escitalopram, bupropion, venlafaxine, mirtazapine, and duloxetine. Due to resistance to traditional medications, she received off-label treatment with ketamine, showing clinical improvement after multiple sessions. Despite initial challenges, the woman reported continued improvement with the ketamine treatment. [Extracted from the article]

A 54-year-old woman developed negative myoclonus while being treated with clozapine and escitalopram for schizophrenia. Her symptoms improved with the medications, but after reaching the target dose of clozapine, she experienced abnormal jerky movements and difficulty walking. The woman was diagnosed with negative myoclonus secondary to the medication therapy and showed improvement after discontinuing clozapine and receiving treatment with clonazepam. [Extracted from the article]

A 38-year-old woman developed drug-induced pruritus while being treated with escitalopram for anxiety and depression symptoms. She experienced itching and a rash on her upper limbs and back after one week of taking the medication. The woman was diagnosed with drug-induced pruritus secondary to escitalopram and was successfully treated with antihistamines and calamine, leading to resolution of her symptoms within five days. This case report was published in the Asian Journal of Pharmaceutical Research and Health Care in June 2024. [Extracted from the article]

A 56-year-old man with post traumatic stress disorder (PTSD) and depression developed drug intolerance and treatment non-compliance while taking escitalopram, fluoxetine, vilazodone, and sertraline. Despite being prescribed these medications, he reported not being compliant and was unable to tolerate them. As a result, his treatment with these drugs was discontinued, and he continued to struggle with significant suicidal ideation. [Extracted from the article]

The article "Multiple drugs: Various toxicities following in-utero exposure: 5 case reports" in Reactions Weekly discusses five cases of foetuses experiencing adverse effects after in-utero exposure to medications such as citalopram, clonazepam, clonidine, escitalopram, fluoxetine, gabapentin, hydroxyzine, methadone, and quetiapine. The cases describe symptoms like generalised hypertonia, bilateral arm stiffening, sucking mouth movements, decerebrate posturing, and asynchronous tremoring of extremities. The mothers received different combinations of these medications during pregnancy, leading to the observed toxicities in the foetuses. [Extracted from the article]

A 31-year-old man with a history of major depressive disorder, generalised anxiety disorder, and alcohol use disorder (AUD) experienced psychosensory activation and perceptual disturbance after abusing psilocybin. He also developed negative cravings upon discontinuing escitalopram for AUD. Following treatment with escitalopram and naltrexone, he achieved euthymia and sobriety, but relapsed into heavy drinking after discontinuing escitalopram and using psilocybin. The man's experience highlights the complex interactions between psychiatric medications, substance abuse, and mental health conditions. [Extracted from the article]

A 20-year-old woman experienced depression while being treated with isotretinoin for cystic acne. She attempted suicide by overdosing on sertraline and amitriptyline. She also did not respond well to several other medications for depression, including sertraline, aripiprazole, escitalopram, modafinil, and venlafaxine. The woman eventually received electroconvulsive therapy, which helped to resolve her depression. [Extracted from the article]

A case report published in Reactions Weekly describes a 31-year-old woman with schizophrenia who developed tardive dyskinesia (TD) while being treated with cariprazine for psychosis. She later experienced worsening of TD and akathisia when she started taking escitalopram for postpsychotic depression. The woman's TD was attributed to cariprazine, while the worsening of TD was attributed to escitalopram. Her TD improved when the cariprazine dose was reduced and she received ginkgo biloba and vitamin E. However, she developed akathisia as a side effect of escitalopram, which resolved after receiving biperiden. [Extracted from the article]

A 19-year-old woman with schizoaffective disorder (SD) experienced a lack of efficacy when treated with sertraline, escitalopram, and venlafaxine. Despite receiving these medications, she continued to have severe depressive episodes, disorganized psychotic symptoms, and persistent suicidal ideation. However, when she switched to vortioxetine, her self-destructive thoughts significantly decreased within eight weeks, and she was able to resume her hobbies and singing. This improvement persisted even after twelve months. [Extracted from the article]

A 54-year-old woman with major depression or schizoaffective disorder exhibited lack of efficacy during treatment with venlafaxine, aripiprazole, escitalopram, valproate, and duloxetine. Despite receiving various medications, her depressive symptoms persisted. However, after switching to moclobemide and adjusting the dosage, she experienced a full response with improved mood, psychomotor features, and speech alterations. After one year of treatment, she remained stable with no emergence of manic or psychotic symptoms. [Extracted from the article]

A 68-year-old woman experienced drug ineffectiveness while being treated with escitalopram and lorazepam for depression and anxiety. She also developed toothache while taking venlafaxine for the same conditions. After being admitted to the hospital, her treatment was changed to venlafaxine and clonazepam, but she experienced severe tooth pain. The toothache was determined to be a side effect of the venlafaxine, and her treatment was adjusted accordingly. Once the venlafaxine was stopped and she started taking sertraline, her symptoms improved. [Extracted from the article]

An 82-year-old woman experienced a lack of efficacy during her treatment for dementia and depressive disorder. She was initially prescribed donepezil for dementia, but after six months, her cognitive disturbances worsened, indicating a lack of effectiveness. She also reported a depressive mood and was subsequently prescribed escitalopram and mirtazapine, but these medications did not lead to any clinical improvement. Eventually, she was started on vortioxetine treatment, which resulted in an improvement in her depressive mood after six months. [Extracted from the article]

An 82-year-old woman experienced a lack of efficacy during her treatment for dementia and depressive disorder. She was initially prescribed donepezil for dementia, but after six months, her cognitive disturbances worsened, indicating a lack of effectiveness. She also reported a depressive mood and was subsequently prescribed escitalopram and mirtazapine, but these medications did not lead to any clinical improvement. Eventually, she was started on vortioxetine treatment, which resulted in an improvement in her depressive mood after six months. [Extracted from the article]

A case study published in Reactions Weekly describes a 22-year-old man who developed mania while being treated with escitalopram, aripiprazole, and desvenlafaxine for panic disorder. The man initially visited a psychiatric clinic with recurrent panic attacks and anticipatory anxiety, and was subsequently diagnosed with panic disorder. He was prescribed escitalopram, desvenlafaxine, and aripiprazole, along with alprazolam and propranolol. However, in August 2022, he reported symptoms of increased impulsivity, overspending, and polydipsia, and was diagnosed with a manic episode. The medications were tapered off and he was treated with lithium and quetiapine, resulting in a return to a stable state. [Extracted from the article]

A 17-year-old boy with a history of attention deficit hyperactivity disorder (ADHD) and developmental delay experienced a lack of efficacy while being treated with escitalopram and methylphenidate for a depressive episode. Despite receiving treatment, his condition worsened and he attempted suicide, leading to his admission to the ICU. He underwent mechanical ventilation and therapeutic hypothermia to prevent brain damage. After developing seizures, he was diagnosed with type 1 bipolar disorder and periventricular heterotopia. His symptoms were eventually stabilized with the use of valproic acid and aripiprazole. [Extracted from the article]

A 13-year-old girl with tic cough was treated with escitalopram and quetiapine, but experienced lack of efficacy. She also developed sleepiness when aripiprazole was added to her treatment. The girl had a medical history of congenital hydrocephalus and underwent surgical treatment two years prior. After three months of therapy, there was no improvement in her tic cough, indicating lack of efficacy. However, after undergoing intensive psychotherapy and discontinuing aripiprazole, her cough gradually reduced and subsided, leading to complete remission. [Extracted from the article]

A 55-year-old man developed leukocytoclastic vasculitis (LCV) while being treated with escitalopram for bipolar disorder. He experienced painful purplish skin lesions that spread from his lower extremities to his thighs and trunk. Tests revealed hypereosinophilia and a skin biopsy confirmed LCV. The man's escitalopram therapy was discontinued and he was treated with prednisolone and cetirizine, which initially improved his condition. However, he later experienced a relapse and died from intraalveolar hemorrhage caused by LCV. [Extracted from the article]

A 52-year-old woman experienced lack of efficacy and developed alcohol use disorder (AUD) while being treated with escitalopram for depression. She was admitted to a facility for assistance with alcohol withdrawal and was diagnosed with severe AUD. Her alcohol use had increased significantly during treatment, and she reported cravings and compulsive alcohol usage. After completing alcohol withdrawal management and tapering off escitalopram, she remained alcohol-free and free of depressive symptoms. It was concluded that her AUD developed as a result of escitalopram treatment. [Extracted from the article]

A 52-year-old man developed thrombocytopenia, a condition characterized by low platelet count, while being treated with escitalopram for depression. The man had acute-on-chronic liver failure and was advised to undergo a liver transplant. After starting escitalopram, his platelet count dropped significantly and did not improve with platelet transfusion. The possibility of drug-induced thrombocytopenia was considered, and when escitalopram was discontinued, the man's platelet count improved. The diagnosis of escitalopram-induced thrombocytopenia was confirmed, and the man later underwent a successful liver transplant. [Extracted from the article]

A 30-year-old woman developed a recurrent rash while being treated with escitalopram and sertraline for generalized anxiety disorder and postpartum depression. The rash first appeared behind her ears after starting escitalopram, and then became more widespread when her dosage was increased. After discontinuing escitalopram and switching to sertraline, she developed another rash on her breast and extremities. A dermatologist confirmed that the rash was a drug reaction. The patient eventually switched to duloxetine and did not experience any further rashes. [Extracted from the article]

A 67-year-old man with a history of coronary atherosclerotic heart disease and prostatitis exhibited a lack of efficacy during treatment with escitalopram and flupentixol/melitracen for depressive state. Despite increasing the dose of escitalopram and switching to flupentixol/melitracen, his symptoms remained unstable. He was eventually diagnosed with major depressive disorder and started on fluoxetine hydrobromide, trazodone, and duloxetine, which significantly improved his symptoms. His condition remained stable during follow-up visits in June 2023. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a prospective observational study of 215 patients to evaluate predefined subset of drugs and its association with QT interval prolongation, et al. patients [ages and sexs not stated] were described who developed QT interval prolongation during the treatment with azithromycin, clindamycin, escitalopram and risperidone [routes, dosages, durations of treatments to reactions onset, outcomes and indiactions not stated]. [Extracted from the article]

A 27-year-old man experienced serotonin syndrome while being treated with escitalopram for depression. He developed sudden involuntary limb movements and was admitted to the hospital. Physical examination revealed ocular clonus, increased tendon reflexes, and myoclonus in the lower extremities. After discontinuing the escitalopram therapy, all symptoms resolved and the man was discharged home. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA female patient [age not stated] exhibited lack of effiacy during treatment with escitalopram, amitriptyline and nortriptyline for anxiety and depression. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 25-year-old man developed drug induced corneal endothelial deposits during anti-depressant therapy with escitalopram and amitriptyline [routes, time to reaction onset and outcome not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is: Drug interaction• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 74-year-old woman developed serotonin syndrome following concomitant administration of escitalopram for depression and clopidogrel for cerebral infarction [routes not stated]. [Extracted from the article]

A case report published in Reactions Weekly describes a 42-year-old man with schizoaffective disorder who experienced a lack of efficacy while being treated with aripiprazole and escitalopram. In addition, the man developed Stevens Johnson syndrome while taking lamotrigine. The patient's symptoms worsened with aripiprazole and escitalopram, and after starting lamotrigine, he developed conjunctivitis, facial swelling, and mucosal erosion of the tongue. He was diagnosed with Stevens Johnson syndrome and treated with prednisone and fluid therapy, eventually improving and being discharged after four days. [Extracted from the article]

The Safety and Strategies for Reinitiating Electroconvulsive Therapy After ECT-Induced Takotsubo Cardiomyopathy: A Case Report and Systematic Review. Thus, she was scheduled for electroconvulsive therapy (ECT). At the time of second ECT, the medications included sertraline, olanzapine along with continuation of irbesartan, aspirin, lansoprazole and linaclotide. [Extracted from the article]

Additionally, the ECG showed prolonged QT interval with 612-ms. Prolongation of QT interval was considered to be secondary to escitalopram. Also, the serum potassium level was 2.84 mmol/L therefore, potassium supplementation was subsequently commenced. On day 9 of admission, her serum potassium level and ECG returned to normal. [Extracted from the article]